OmarNissMD
Pediatric Hematology & Oncology • Cincinnati, OHPediatric Anemia and Red Blood Cell Hematology, Pediatric Platelet Disorder Hematology
Physician
Dr. Niss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
Cincinnati, OH 45229Phone+1 513-636-4200
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 2010 - 2013
University of Nebraska Medical Center College of MedicineResidency, Pediatrics, 2007 - 2010
Jordan University of Science and Technology FOMClass of 2004
Certifications & Licensure
OH State Medical License 2010 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
- Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease Start of enrollment: 2014 Jan 31
Publications & Presentations
PubMed
- Genetic variants in canonical Wnt signaling pathway associated with pediatric immune thrombocytopenia.Taylor Olmsted Kim, Jennifer M Geris, Jonathan M Flanagan, Rachael F Grace, Michele P Lambert
Blood Advances. 2024-11-12 - 10 citationsEarly hydroxyurea use is neuroprotective in children with sickle cell anemia.Kristine Karkoska, Amanda Pfeiffer, Dean W Beebe, Charles T Quinn, Omar Niss
American Journal of Hematology. 2022-10-01 - 8 citationsEarly initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia.Omar Niss, Jon Detterich, John C Wood, Thomas D Coates, Punam Malik
Blood. 2022-09-15
Abstracts/Posters
- VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental DelayOmar Niss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Diseas...Omar Niss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Disease-Modifying Therapies Remain Underused in SCD Despite Safety and EfficacyDecember 7th, 2024
Identifying Causes of Cardiomyopathy in Patients with Sickle Cell AnemiaJune 22nd, 2017
Researchers ID Key Drivers of Heart Complications in Sickle Cell AnemiaAugust 9th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
